VA studies to tap into Million Veteran database

The Department of Veterans Affairs is funding four new studies that will tap into the national, voluntary research Million Veteran Program (MVP) which has enrolled more than 390,000 veterans to date.

As part of a data access beta test, the newly-funded studies will leverage the database of veterans receiving their care in the VA healthcare system. MVP is the nation's largest database linking genetic, clinical, lifestyle and military exposure information.  

The goal is to ultimately enroll 1 million veterans in MVP’s genomic database which includes DNA specimens and links to tissue specimens, as well as access to the VA’s EHR system, an IT capability to identify patients for a variety of types of studies and analytical tools. 

The studies also will help establish new methods for securely linking MVP data with other sources of health information, including non-VA sources such as the Centers for Medicaid & Medicare Services.

The studies will target understudied African American and Hispanic veteran populations and address questions related to common chronic illnesses: cardiovascular risk factors, metabolic conditions, multi-substance use; and pharmacogenomics of kidney disease.

“There’s already been an impressive amount of data collected through MVP, and we’re continuing to engage more veterans in the program and building its research infrastructure through studies like these,” said Timothy O’ Leary, MD, PhD, VA’s chief research and development officer, in a release.

MVP-based studies on bipolar disorder, post-traumatic stress disorder and schizophrenia already are underway. 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.